Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Albany Molecular Res (AMRI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 711,779
  • Shares Outstanding, K 42,930
  • Annual Sales, $ 570,450 K
  • Annual Income, $ -70,170 K
  • 36-Month Beta 1.28
  • Price/Sales 1.25
  • Price/Cash Flow 8.30
  • Price/Book 2.38

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.14 +26.18%
on 03/28/17
18.03 -8.04%
on 04/25/17
+3.12 (+23.18%)
since 03/27/17
3-Month
13.01 +27.44%
on 03/23/17
18.99 -12.69%
on 02/15/17
-1.69 (-9.25%)
since 01/27/17
52-Week
12.45 +33.17%
on 05/12/16
19.35 -14.32%
on 01/05/17
+0.98 (+6.28%)
since 04/27/16

Most Recent Stories

More News
SSCI Receives a 2017 Biotechnology Award for Global Research and Manufacturing

SSCI, a division of Albany Molecular Research Inc. (AMRI), has been recognized by Global Health & Pharma (GHP) magazine as the winner of the 2017 Biotechnology Award for Best Global Research & Manufacturing...

AMRI : 16.58 (+0.06%)
AMRI Schedules First Quarter 2017 Earnings Release and Conference Call

AMRI (NASDAQ: AMRI) today announced it will issue first quarter 2017 financial results before the opening of the market on Tuesday, May 9, 2017. Following the release of its results, the company will...

AMRI : 16.58 (+0.06%)
Denovo Biopharma Obtains Exclusive License To Liafensine From AMRI

Denovo Biopharma LLC, today announced that it has obtained an exclusive license to liafensine (DB104), a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI), a late-stage CNS drug, from Albany...

AMRI : 16.58 (+0.06%)
Albany Molecular Research Down 18.0% Since SmarTrend Downtrend Call (AMRI)

SmarTrend identified a Downtrend for Albany Molecular Research (NASDAQ:AMRI) on January 20th, 2017 at $17.67. In approximately 3 months, Albany Molecular Research has returned 17.97% as of today's recent...

AMRI : 16.58 (+0.06%)
Albany Molecular Research Rises 7.32% on Heavy Volume: Watch For Potential Pullback

Albany Molecular Research (NASDAQ:AMRI) traded in a range yesterday that spanned from a low of $14.14 to a high of $15.00. Yesterday, the shares gained 7.3%, which took the trading range above the 3-day...

AMRI : 16.58 (+0.06%)
Downtrend Call Working As Albany Molecular Research Stock Falls 21.0% (AMRI)

SmarTrend identified a Downtrend for Albany Molecular Research (NASDAQ:AMRI) on January 20th, 2017 at $17.67. In approximately 2 months, Albany Molecular Research has returned 21.03% as of today's recent...

AMRI : 16.58 (+0.06%)
Albany Molecular Research Down 24.8% Since SmarTrend Downtrend Call (AMRI)

SmarTrend identified a Downtrend for Albany Molecular Research (NASDAQ:AMRI) on January 20th, 2017 at $17.67. In approximately 2 months, Albany Molecular Research has returned 24.77% as of today's recent...

AMRI : 16.58 (+0.06%)
SSCI and Whitehouse Laboratories to Exhibit at Interphex 2017

SSCI and Whitehouse Laboratories, divisions of Albany Molecular Research, Inc, are looking forward to exhibiting at the INTERPHEX 2017! Sponsored by the Parenteral Drug Association (PDA), the New York...

AMRI : 16.58 (+0.06%)
Albany Molecular Research Has Returned 23.4% Since SmarTrend Recommendation (AMRI)

SmarTrend identified a Downtrend for Albany Molecular Research (NASDAQ:AMRI) on January 20th, 2017 at $17.67. In approximately 2 months, Albany Molecular Research has returned 23.35% as of today's recent...

AMRI : 16.58 (+0.06%)
AMRI Announces Agreement with Accord Healthcare to Jointly Develop, Manufacture and Commercialize Parenteral Drug Products

AMRI (NASDAQ: AMRI) today announced that it has entered into an agreement with the pharmaceutical group Ferrer and Accord Healthcare, Inc. ("Accord Healthcare") to jointly develop and manufacture an undisclosed...

AMRI : 16.58 (+0.06%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

See More

Business Summary

Albany Molecular Research is an integrated provider of drug discovery and development, chemistry research and manufacturing services. They offer services traditionally provided by chemistry divisions within pharmaceutical and biotechnology companies, including drug discovery, medicinal chemistry, chemical...

See More

Support & Resistance

2nd Resistance Point 17.53
1st Resistance Point 17.05
Last Price 16.58
1st Support Level 16.22
2nd Support Level 15.87

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.